Browsing by Author "Edvardsen, Thor"

Now showing 1 - 11 of 11

COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel
(2020) Skulstad, Helge; Cosyns, Bernard; Popescu, Bogdan A.; Galderisi, Maurizio; Di Salvo, Giovanni; Donal, Erwan; Petersen, Steffen; Gimelli, Alessia; Haugaa, Kristina H.; Muraru, Denisa; Almeida, Ana G.; Schulz-Menger, Jeanette; Dweck, Marc R.; Pontone, Gianluca; Sade, Leyla Elif; Gerber, Bernhard; Maurovich-Horvat, Pal; Bharucha, Tara; Cameli, Matteo; Magne, Julien; Westwood, Mark; Maurer, Gerald; Edvardsen, Thor; 32242891
EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review
(2017) Sade, Elif; Steeds, Richard P.; Garbi, Madalina; Cardim, Nuno; Kasprzak, Jaroslaw D.; Nihoyannopoulos, Petros; Popescu, Bogdan Alexandru; Stefanidis, Alexandros; Cosyns, Bernard; Monaghan, Mark; Aakhus, Svend; Edvardsen, Thor; Flachskampf, Frank; Galiuto, Leonarda; Athanassopoulos, George; Lancellotti, Patrizio; 28329307
The European Association for Cardiovascular Imaging (EACVI) has outlined the rationale for setting appropriate use criteria (AUC) in cardiovascular (CV) imaging. Transthoracic echocardiography (TTE) is the most common imaging modality in CV disease and is a central tool in diagnosis, follow-up, management planning and intervention. The purpose of AUC is to inform referrers, both to avoid under-use, which may result in incomplete or incorrect diagnosis and treatment, and also over-use, which may delay correct diagnosis, lead to 'treatment cascade', and wastes resources. The first step in defining AUC for TTE in the adult has been for a panel of experts in echocardiography to review the evidence, guidelines, recommendations, and position papers from the European Society of Cardiology, EACVI and other specialist societies, and current state-of-the-art clinical practice. The attached document summarizes this work, which will be used to under-pin the development of AUC.
EuroEcho 2019: highlights
(2020) Magne, Julien; Bharucha, Tara; Cikes, Maya; Galderisi, Maurizio; Price, Suzanna; Sade, Leyla Elif; Popescu, Bogdan A.; Cosyns, Bernard; Edvardsen, Thor; 32182333
The annual meeting of the European Association of Cardiovascular Imaging, EuroEcho 2019, was held in Vienna, Austria, in December 2019. In this article, we present a summary of the 'Highlights' session.
Global evaluation of echocardiography in patients with COVID-19
(2020) Dweck, Marc R.; Bularga, Anda; Hahn, Rebecca T.; Bing, Rong; Lee, Kuan Ken; Chapman, Andrew R.; White, Audrey; Di Salvo, Giovanni; Sade, Leyla Elif; Pearce, Keith; Newby, David E.; Popescu, Bogdan A.; Donal, Erwan; Cosyns, Bernard; Edvardsen, Thor; Mills, Nicholas L.; Haugaa, Kristina; 32556199
Aims To describe the cardiac abnormalities in patients with COVID-19 and identify the characteristics of patients who would benefit most from echocardiography. Methods and results In a prospective international survey, we captured echocardiography findings in patients with presumed or confirmed COVID-19 between 3 and 20 April 2020. Patient characteristics, indications, findings, and impact of echocardiography on management were recorded. Multivariable logistic regression identified predictors of echocardiographic abnormalities. A total of 1216 patients [62 (52-71) years, 70% male] from 69 countries across six continents were included. Overall, 667 (55%) patients had an abnormal echocardiogram. Left and right ventricular abnormalities were reported in 479 (39%) and 397 (33%) patients, respectively, with evidence of new myocardial infarction in 36 (3%), myocarditis in 35 (3%), and takotsubo cardiomyopathy in 19 (2%). Severe cardiac disease (severe ventricular dysfunction or tamponade) was observed in 182 (15%) patients. In those without pre-existing cardiac disease (n = 901), the echocardiogram was abnormal in 46%, and 13% had severe disease. Independent predictors of left and right ventricular abnormalities were distinct, including elevated natriuretic peptides [adjusted odds ratio (OR) 2.96, 95% confidence interval (CI) 1.75-5.05) and cardiac troponin (OR 1.69, 95% CI 1.13-2.53) for the former, and severity of COVID-19 symptoms (OR 3.19, 95% CI 1.73-6.10) for the latter. Echocardiography changed management in 33% of patients. Conclusion In this global survey, cardiac abnormalities were observed in half of all COVID-19 patients undergoing echocardiography. Abnormalities were often unheralded or severe, and imaging changed management in one-third of patients.
Rational and design of EuroCRT: an international observational study on multi-modality imaging and cardiac resynchronization therapy
(2017) Sade, Elif; Donal, Erwan; Delgado, Victoria; Magne, Julien; Bucciarelli-Ducci, Chiara; Leclercq, Christophe; Cosyns, Bernard; Sitges, Marta; Edvardsen, Thor; Stankovic, Ivan; Agricola, Eustachio; Galderisi, Maurizio; Lancellotti, Patrizio; Hernandez, Alfredo; Plein, Sven; Muraru, Denisa; Schwammenthal, Ehud; Hindricks, Gerhard; Popescu, Bogdan A.; Habib, Gilbert; 28329299
Aims Assessment of left ventricular (LV) volumes and ejection fraction (LVEF) with cardiac imaging is important in the selection of patients for cardiac resynchronization therapy (CRT). Several observational studies have explored the role of imaging-derived LV dyssynchrony parameters to predict the response to CRT, but have yielded inconsistent results, precluding the inclusion of imaging-derived LV dyssynchrony parameters in current guidelines for selection of patients for CRT. Methods The EuroCRT is a large European multicentre prospective observational study led by the European Association of Cardiovascular Imaging. We aim to explore if combing the value of cardiac magnetic resonance (CMR) and echocardiography could be beneficial for selecting heart failure patients for CRT in terms of improvement in long-term survival, clinical symptoms, LV function, and volumes. Speckle tracking echocardiography will be used to assess LV dyssynchrony and wasted cardiac work whereas myocardial scar will be assessed with late gadolinium contrast enhanced CMR. All data will be measured in core laboratories. The study will be conducted in European centres with known expertise in both CRT and multimodality cardiac imaging.
Rationale and design of the EACVI AFib Echo Europe Registry for assessing relationships of echocardiographic parameters with clinical thrombo-embolic and bleeding risk profile in non-valvular atrial fibrillation
(2018) Sade, Leyla Elif; Galderisi, Maurizio; Donal, Erwan; Magne, Julien; Lo Iudice, Francesco; Agricola, Eustachio; Cameli, Matteo; Schwammenthal, Ehud; Cardim, Nuno; Cosyns, Bernard; Hagendorff, Andreas; Neskovic, Alexandar N.; Luis Zamorano, Jose; Lancellotti, Patrizio; Habib, Gilbert; Edvardsen, Thor; Popescu, Bogdan A.; 0000-0003-3737-8595; 29474699; AAQ-7583-2021
The European Society of Cardiology (ESC) guidelines for management of atrial fibrillation (AF) recommend the use of CHA(2)DS(2)VASc risk score for assessment of thromboembolic (TE) risk, whereas the stratification of bleeding risk should be obtained by HAS-Bleed to balance the most appropriate anticoagulation (OAC) therapy. However, men with CHA(2)DS(2)VASc score=1 and women with CHA(2)DS(2)VASc=2, who are at intermediate TE risk, represent a grey zone where guidelines do not provide a definite OAC indication. Accordingly, implementation of risk stratification with echocardiography could be extremely useful. Both prospective and cross-sectional studies on transthoracic echocardiography (TTE) prediction of TE events and studies utilizing transoesophageal echocardiographic parameters as surrogate markers of TE events makes sustainable the hypothesis that echocardiography could improve TE prediction in non-valvular AF. Moreover, considering the close association of AF and stroke, all echo-Doppler parameters that have shown to predict AF onset and recurrence could be useful also to predict TE events in this clinical setting. Accordingly, EACVI AFib Echo Europe Registry has been designed as an observational, cross-sectional study, with the aim of evaluating: (i) left atrial (LA) size and function together with left ventricular geometry, systolic and diastolic functions in paroxysmal, persistent, and permanent AF; (ii) relationships of structural/ functional parameters with clinical TE and bleeding risk profile. By the AFib Echo Europe Registry, we expect to collect data on echocardiographic phenotype of patients with AF. The large data set accumulated will be useful to test the level of agreement of different echocardiographic measurements with the available risk scores.
Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging
(2017) Sade, Leyla Elif; Galderisi, Maurizio; Cosyns, Bernard; Edvardsen, Thor; Cardim, Nuno; Delgado, Victoria; Di Salvo, Giovanni; Donal, Erwan; Ernande, Laura; Garbi, Madalina; Grapsa, Julia; Hagendorff, Andreas; Kamp, Otto; Magne, Julien; Santoro, Ciro; Stefanidis, Alexandros; Lancellotti, Patrizio; Popescu, Bogdan; Habib, Gilbert; 0000-0003-3737-8595; 29045589; AAQ-7583-2021
Aims This European Association Cardiovascular Imaging (EACVI) Expert Consensus document aims at defining the main quantitative information on cardiac structure and function that needs to be included in standard echocardiographic report following recent ASE/EACVI chamber quantification, diastolic function, and heart valve disease recommendations. The document focuses on general reporting and specific pathological conditions such as heart failure, coronary artery and valvular heart disease, cardiomyopathies, and systemic diseases. Methods and results Demographic data (age, body surface area, blood pressure, and heart rhythm and rate), type (vendor and model) of ultrasound system used and image quality need to be reported. In addition, measurements should be normalized for body size. Reference normal values, derived by ASE/EACVI recommendations, shall always be reported to differentiate normal from pathological conditions. This Expert Consensus document suggests avoiding the surveillance of specific variable using different ultrasound techniques (e.g. in echo labs with high expertise in left ventricular ejection fraction by 3D and not by 2D echocardiography). The report should be also tailored in relation with different cardiac pathologies, quality of images, and needs of the caregivers. Conclusion The conclusion should be concise reflecting the status of left ventricular structure and function, the presence of left atrial and/or aortic dilation, right ventricular dysfunction, and pulmonary hypertension, leading to an objective communication with the patient health caregiver. Variation over time should be considered carefully, taking always into account the consistency of the parameters used for comparison.
The structural heart disease interventional imager rationale, skills and training: a position paper of the European Association of Cardiovascular Imaging
(2021) Agricola, Eustachio; Ancona, Francesco; Brochet, Eric; Donal, Erwan; Dweck, Marc; Faletra, Francesco; Lancellotti, Patrizio; Mahmoud Elsayed, Hani; Marsan, Nina Ajmone; Maurovich Hovart, Pal; Monaghan, Mark; Ribeiro, Jose; Sade, Leyla Elif; Swaans, Martin; Von Bardeleben, Ralph Stephan; Wunderlich, Nina; Zamorano, Jose-Luis; Popescu, Bogdan A.; Cosyns, Bernard; Edvardsen, Thor; 0000-0003-3737-8595; 33564848; AAQ-7583-2021
Percutaneous therapeutic options for an increasing variety of structural heart diseases (SHD) have grown dramatically. Within this context of continuous expansion of devices and procedures, there has been increased demand for physicians with specific knowledge, skills, and advanced training in multimodality cardiac imaging. As a consequence, a new subspecialty of 'Interventional Imaging' for SHD interventions and a new dedicated professional figure, the 'Interventional Imager' with specific competencies has emerged. The interventional imager is an integral part of the heart team and plays a central role in decision-making throughout the patient pathway, including the appropriateness and feasibility of a procedure, pre-procedural planning, intra-procedural guidance, and post-procedural follow-up. However, inherent challenges exist to develop a training programme for SHD imaging that differs from traditional cardiovascular imaging pathways. The purpose of this document is to provide the standard requirements for the training in SHD imaging, as well as a starting point for an official certification process for SHD interventional imager.
Training, competence, and quality improvement in echocardiography the European Association of Cardiovascular Imaging Recommendations: update 2020
(2020) Popescu (Chair), Bogdan A.; Stefanidis, Alexandros; Fox, Kevin F.; Cosyns, Bernard; Delgado, Victoria; Di Salvo, Giovanni Di; Donal, Erwan; Flachskampf, Frank A.; Galderisi, Maurizio; Lancellotti, Patrizio; Muraru, Denisa; Sade, Leyla Elif; Edvardsen, Thor; 33245758
The primary mission of the European Association of Cardiovascular Imaging (EACVI) is 'to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging'. Echocardiography is a key component in the evaluation of patients with known or suspected cardiovascular disease and is essential for the high quality and effective practice of clinical cardiology. The EACVI aims to update the previously published recommendations for training, competence, and quality improvement in echocardiography since these activities are increasingly recognized by patients, physicians, and payers. The purpose of this document is to provide the general requirements for training and competence in echocardiography, to outline the principles of quality evaluation, and to recommend a set of measures for improvement, with the ultimate goal of raising the standards of echocardiographic practice. Moreover, the document aims to provide specific guidance for advanced echo techniques, which have dramatically evolved since the previous publication in 2009.
The year 2019 in the European Heart Journal - Cardiovascular Imaging: part II
(2020) Cosyns, Bernard; Haugaa, Kristina H.; Gerber, Bernrhard; Gimelli, Alessia; Sade, Leyla Elif; Maurer, Gerald; Popescu, Bogdan A.; Edvardsen, Thor; 33188688
The European Heart Journal - Cardiovascular Imaging was Launched in 2012 and has during these years become one of the leading multimodality cardiovascular imaging journal. The journal is now established as one of the top cardiovascular journals and is the most important cardiovascular imaging journal in Europe. The most important studies published in our Journal from 2019 will be highlighted in two reports. Part II will focus on valvular heart disease, heart failure, cardiomyopathies, and congenital heart disease. While Part I of the review has focused on studies about myocardial function and risk prediction, myocardial ischaemia, and emerging techniques in cardiovascular imaging.
The year 2020 in the European Heart Journal-Cardiovascular Imaging: part II
(2021) Cosyns, Bernard; Sade, Leyla Elif; Gerber, Bernhard L.; Gimelli, Alessia; Muraru, Denisa; Maurer, Gerald; Edvardsen, Thor; 34718480
The European Heart Journal-Cardiovascular Imaging was launched in 2012 and has during these years become one of the leading multimodality cardiovascular imaging journal. The journal is now established as one of the top cardiovascular journals and is the most important cardiovascular imaging journal in Europe. The most important studies published in our Journal from 2020 will be highlighted in two reports. Part II will focus on valvular heart disease, heart failure, cardiomyopathies, and congenital heart disease. While Part I of the review has focused on studies about myocardial function and risk prediction, myocardial ischaemia, and emerging techniques in cardiovascular imaging.